Trivalent inactivated influenza vaccine

Trivalent inactivated influenza vaccine has been studied in 4 papers since 2016: 1 trial and 1 observational study in people, 2 in animals. The newest paper, Feb 2, 2020: “Strain specificities in influence of ageing on germinal centre reaction to inactivated influenza virus antigens in mice: Sex-based differences”.

4 papers study it1 findingUpdated Feb 2, 2020

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country; 1 trial, 1 about aging.

“seasonal influenza vaccination elicits limited cross-reactive ADP to HA in both young and older adults.”

1 study gave trivalent inactivated influenza vaccine to people and measured what changed.

What changed	Design	People	Source
up: Induces cross-reactive antibody-dependent phagocytosisLimited cross-reactivity	Trial	over and under 60 yearsOlder adults; healthy Australian adults	Vaccine, Oct 10, 2017

Studies of trivalent inactivated influenza vaccine measured 1 outcome; the most studied are cross-reactive antibody-dependent phagocytosis (1 study).

Cross-reactive antibody-dependent phagocytosis

upin humans1

1 study

Trivalent inactivated influenza vaccine induces cross-reactive antibody-dependent phagocytosis in humans (healthy Australian adults) (Limited cross-reactivity).
“seasonal influenza vaccination elicits limited cross-reactive ADP to HA in both young and older adults.”
Human trialhealthy Australian adults2008 trivalent inactivated vaccine
Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults
VaccineOct 10, 2017